Euroscreen, a Gosselies, Belgium-based drug development company, completed a €16m Series B funding round.
The round was co led by SFPI-FPIM and Fund+ with participation from existing shareholders Vesalius Biocapital II Partners, SRIW SA, BNP Paribas Fortis Private Equity, and new investor Capricorn Health-Tech Fund NV.
The company intends to use the funds to extend its drug candidate ESN364 development:
(i) filing an IND in US;
(ii) preforming long term toxicology studies to support future clinical chronic treatment; and
(iii), supporting the ongoing Phase II clinical trials vs. menopausal Hot Flashes, PCOS and UF.
Led by Jean Combalbert, CEO, Euroscreen is progressing ESN364, a proprietary, oral, small-molecule for the purpose of the treatment of Women’s Health Disorders. It has showed promising expectations in the treatment of menopausal Hot Flashes and other Women’s Health Disorders such as, PolyCystic ovary syndrome (PCOS), Uterine Fibroids (UF) and Endometriosis.
FinSMEs
02/10/2015